• Founded in 2012
  • Employees: 10

Description :

ImmunoLogik GmbH is developing an innovative drug for the efficient and vital treatment of untreated patients, who would otherwise die as a result of the onset of AIDS. The drug is targeted to attack the building blocks of the host cell , which are essential for the propagation of HIV. The objective is to significantly reduce the risk of developing resistant virus variants.

Headquarters :

Am Borsigturm 100, 13507 Berlin

Related Posts

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.